Arrhythmias
Özet
Rheumatic diseases (RD) significantly impact cardiovascular health, often leading to arrhythmias due to myocardial inflammation, fibrosis, and structural remodeling. Inflammatory processes, oxidative stress, and autoantibody activity contribute to these disturbances. Supraventricular arrhythmias, particularly atrial fibrillation (AF), are common in patients with conditions like rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. These arrhythmias increase the risk of stroke and mortality, especially in patients with rheumatic heart disease (RHD).
Management strategies include immunosuppressive therapy for the underlying disease alongside antiarrhythmic medications such as beta-blockers and calcium channel blockers. Amiodarone is often recommended for rhythm control, while anticoagulation therapy is crucial in AF patients with RHD to prevent thromboembolic events. In cases of drug resistance or severe ventricular arrhythmias, interventions like radiofrequency ablation and implantable cardioverter defibrillators (ICDs) may be necessary.
Early diagnosis using ECG, echocardiography, and cardiac MRI is essential to prevent complications. Despite the prevalence of arrhythmias in RD, current guidelines are insufficient, emphasizing the need for further research and updated clinical protocols. Rheumatic AF requires specific therapeutic approaches to improve outcomes and reduce cardiovascular risks.
Romatizmal hastalıklar (RH), kardiyovasküler sağlığı önemli ölçüde etkileyerek miyokardit, fibrozis ve yapısal yeniden şekillenme nedeniyle aritmilere yol açabilir. İnflamatuar süreçler, oksidatif stres ve otoantikor aktivitesi bu bozukluklara katkıda bulunur. Romatoid artrit, sistemik skleroz ve sistemik lupus eritematozus gibi hastalıklarda supraventriküler aritmiler, özellikle atriyal fibrilasyon (AF), yaygındır. Bu aritmiler, özellikle romatizmal kalp hastalığı (RKH) olan hastalarda inme ve ölüm riskini artırır.
Tedavi stratejileri, temel hastalığın immünosupresif tedavisi ile birlikte beta-blokerler ve kalsiyum kanal blokerleri gibi antiaritmik ilaçları içerir. Ritim kontrolünde genellikle amiodaron önerilirken, RKH'li AF hastalarında tromboembolik olayları önlemek için antikoagülan tedavi kritik öneme sahiptir. İlaç direnci veya şiddetli ventriküler aritmiler durumunda, radyofrekans ablasyon ve implante edilebilir kardiyoverter defibrilatörler (ICD) gibi girişimler gerekebilir.
Komplikasyonları önlemek için EKG, ekokardiyografi ve kardiyak MRG gibi yöntemlerle erken tanı oldukça önemlidir. RH'de aritmiler yaygın olmasına rağmen mevcut kılavuzlar yetersizdir ve bu durum daha fazla araştırma ve güncel klinik protokollerin gerekliliğini vurgulamaktadır. Romatizmal AF, sonuçları iyileştirmek ve kardiyovasküler riskleri azaltmak için özel tedavi yaklaşımları gerektirir.
Referanslar
Lazzerini PE, Capecchi PL, Guideri F, et al. Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev 2006;5:306–13. https://doi.org/10.1016/j. autrev.2005.11.002.
Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015;12:e41–63. https://doi.org/10.1016/j. hrthm.2015.03.029.
Moutsopoulos HM, Zampeli E, eds. Immunology and Rheumatology in Questions. 2nd ed. Cham, Switzerland: Springer Nature, 2021. https://doi.org/10.1007/978-3-030- 56670-8.
Mavrogeni S, Gargani L, Pepe A, et al. Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology (Oxford) 2020;59:1938–48. doi: 10.1093/rheumatology/kez494.
Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007;49:1642–8. https://doi.org/10.1016/j. jacc.2006.12.042.
Teixeira RA, Borba EF, Bonfá E, et al. Arrhythmias in systemic lupus erythematosus. Rev Bras Reumatol 2010;50:81–9. https://doi.org/10.1590/S0482- 50042010000100008.
Guzmán J, Cardiel MH, Arce-Salinas A, et al. The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus. J Rheumatol 1994;21:1845–8
Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97– 111. https://doi.org/10.1093/qjmed/hci015.
Gawałko M, Balsam P, Lodziński P, et al. Cardiac arrhythmias in autoimmune diseases. Circ J 2020;84:685–94. https://doi. org/10.1253/circj.CJ-19-0705.
Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin North Am 2014;40:11–26. https://doi.org/10.1016/j. rdc.2013.10.006.
Ferri C, Bernini L, Bongiorni MG, et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with multisystemic symptoms, in progressive systemic sclerosis patients. Arthritis Rheum 1985;28:1259–66. doi: 10.1002/art.1780281110
James TN, Rupe CE, Monto RW. Pathology of the cardiac conduction system in systemic lupus erythematosus. Ann Intern Med 1965;63:402–10. https://doi.org/10.7326/0003- 4819-63-3-402.
Roberts NK, Cabeen WR Jr, Moss J, et al. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981;94:38–40. https://doi. org/10.7326/0003-4819-94-1-38.
Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7. https://doi. org/10.1161/01.CIR.0000054612.26458.B2.
Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 2009;60:1187–92. https://doi.org/10.1002/art.24386.
Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018;72:3158–76. https://doi.org/10.1016/j.
Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias. Europace 2017;19:465–511. https://doi.org/10.1093/europace/euw444.
Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011;343:d3450. https://doi.org/10.1136/bmj.d3450.
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J 2017;38:1717–27. https://doi.org/10.1093/ eurheartj/ehw208.
Watkins D.A.,Johnson C.O.,Colquhoun S.M.,et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. 2017;377:713–722. doi: 10.1056/NEJMoa1603693
Noubiap J.J., Nyaga U.F., Ndoadoumgue A.L., et al. Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease. Glob Heart. 2020;15:38 doi: 10.5334/gh.807
Kim H.-J., Cho G.-Y., Kim Y-J., et al. Development of atrial fibrillation in patients with rheumatic mitral valve disease in sinus rhythm. Int J Cardiovasc Imaging. 2015;31:735–742. doi: 10.1007/s10554-015-0613-2
Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2021;42:373–498 doi: 10.1093/eurheartj/ehaa612
De Caterina R., Camm A.J. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. Europace. 2016;18:6–11. doi: 10.1093/europace/euv288
Lip G.Y.H., Jensen M., Melgaard L.,et al. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating ‘valvular heart disease’ in a nationwide cohort study. Europace. 2019;21:33–40 doi: 10.1093/europace/euy151
Connolly S.J., Karthikeyan G., Ntsekhe M., et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. N Engl J Med. 2022;387:978–988. doi: 10.1056/NEJMc2213437
Yokoyama Y., Briasoulis A.,Ueyama H., et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a meta-analysis. J Thorac Cardiovasc Surg. 2021 Jul 29 doi: 10.1016/j.jtcvs.2021.07.034
Hill J.A., Panza J.A., Michler R.E., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2016;358:1511–1520 doi: 10.1056/NEJMoa070878
Karthikeyan G., Devasenapathy N.,Zühlke L.,et al. Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. Heart. 2019;105:363–369 doi: 10.1136/heartjnl-2018-313614
Vlachos K., Letsas K.P., Korantzopoulos P., et al. A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation. J Geriatr Cardiol. 2015;12:547–554. doi:10.11909/j.issn.1671-5411.2015.05.005
Hu C.L. Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study. Heart. 2006;92:1096–1101 doi:10.1136/hrt.2005.080325
Iung B., Leenhardt A., Extramiana F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart. 2018;104:1062–1068. doi: 10.1136/heartjnl-2017-311425
Sharma G., Anantha Krishnan R., Bohra V., et al. Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy. Indian Heart J. 2016;68:486–492 doi: 10.1016/j.ihj.2015.11.013
Machino T., Tada H., Sekiguchi Y., et al. Hybrid therapy of radiofrequency catheter ablation and percutaneous transvenous mitral commissurotomy in patients with atrial fibrillation and mitral stenosis. J Cardiovasc Electrophysiol. 2010;21:284–289 doi: 10.1111/j.1540-8167.2009.01625.x.
Chen H., Yang B., Ju W., et al. Substrate characteristics and ablation outcome of left atrial tachycardia in rheumatic mitral valve disease. Pacing Clin Electrophysiol. 2017;40:924–931.doi: 10.1111/pace.13099
Ma J., Wei P., Yan Q., et al. Safety and efficacy of concomitant ablation for atrial fibrillation in rheumatic mitral valve surgery: a meta-analysis. J Card Surg. 2022;37:361–373. doi: 10.1111/jocs.16118
